Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs

Title:Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs

Volume: 16 Issue: 10

Author(s): Chiranjib Chakraborty, Minna J. Hsu and Govindasamy Agoramoorthy

Affiliation:

Keywords: Asia, Diabetes, drugs, enzymes, pharcogenomics, T2D.

Abstract: The type 2 diabetes or T2D mellitus has turn into an epidemic throughout the globe in recent years. Various forms of treatment modalities have been available for patients with T2D with some major classes of approved drugs that include Sulfonylureas, Meglitinides, Biguanides, Thiazolidinedione, Alpha-glucosidase inhibitors, GLP-1 analogs, DPP-4 Inhibitors, and SGLT2 inhibitors. This review focuses on the drug metabolizing enzymes (DME), gene polymorphisms, and inter-individual variability in therapeutics including adverse reaction effects involving Phase-I DME and Phase-II in general. This review also covers some key anti-diabetic drugs with respect to their pharcogenomics.

Cite this article as:

Chakraborty Chiranjib, Hsu J. Minna and Agoramoorthy Govindasamy, Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs, Current Drug Metabolism 2015; 16(10) . https://dx.doi.org/10.2174/138920021610151210183821